No Data
Stocks that moved the previous day part 2: Mitsubishi Logistics Next, G.C. Planning, Japan Rad, etc.
Stock name <code> Closing price on the 9th ⇒ Change from previous day ACCESS <4813> 909 -30 Continued caution regarding inappropriate revenue recognition. Trichemical Research Institute <4369> 2780 -106 Small and medium-sized semiconductor-related stocks are also sluggish due to the decline in semiconductor stocks. Mitsukoshi Isetan <3099> 2259 -66 The movement of expectations for china inbound has temporarily calmed down. SCREEN <7735> 9406 -259 Continued selling pressure on main semiconductor-related stocks. F&LC <3563> 3485 -6.
Active and newly listed stocks during the morning session.
*Elan <6099> 732 +63 Although there are no particularly significant materials, buying on dips gathers in the low price range. *Ceres <3696> 3385 +265 Cryptocurrency-related assets continue to gain popularity. *Rakuten Group <4755> 923 +60.1 The shareholder benefits announced last weekend are seen as positive materials. *Marui Steel Pipe <5463> 3479 +221 Announced implementation of a large-scale share buyback. *AZ Maruwa HD <9090> 1137 +68 FMAR is expected to rise to become a major shareholder. *Change HD <396
Strong performance, supported by the rise in nasdaq and the decline in U.S. long-term gold rates.
[Emerging markets individual stock strategy] Today, a solid development is expected in the emerging markets. Last weekend, on the 6th in the US stock market, the Dow Jones Industrial Average fell by 123.19 points (-0.28%) to 44,642.52 points, continuing the decline. Expectations for additional rate cuts at the December Federal Open Market Committee (FOMC) meeting increased after the employment statistics, but the Dow turned down due to the decline of managed healthcare company UnitedHealth (UNH). The NASDAQ, supported by early rate cut expectations, moved steadily throughout the day and reached its all-time high for several consecutive days.
Ain HD, 2Q operating profit decreased by 32.9% to 5.872 billion yen.
Ain HD (9627) announced its performance for the second quarter of the fiscal year ending April 2025, with revenue increasing by 10.9% year-on-year to 214.8 billion yen, and operating profit decreasing by 32.9% to 5.872 billion yen. The main pharmacy business saw an increase in the prescription of high-priced pharmaceuticals, leading to a rise in prescription unit prices. However, factors such as the impact of the June reimbursement revision for pharmacy fees affected the results. [Positive rating] Renascience (4889) revised | Kanamoto (9678) full year [Hold] (381)
Nippon Ski Resort Development: Summary of Financial Results for the 1st Quarter of the Fiscal Year Ending 2025/7 [Japanese GAAP] (Consolidated)
Nippon Ski Resort Devt 1Q Loss Y37.00M Vs Loss Y77.00M